Delving into the Latest Updates on Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine, Genetically engineered subunit vaccine

Synonyms

Bivalent recombinant Norovirus vaccine, Norovirus Bivalent (GI.1 / GII.4) Vaccine National Vaccine and Serum Institute, 双价重组诺如病毒疫苗

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Norovirus Infections

Inactive Indication-

Originator Organization

Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd

Active Organization

Lanzhou Institute of Biological Products Co. Ltd.

Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd

Beijing Bio-Institute Biological Products Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

评价6月龄~59岁健康人群接种不同剂量重组诺如病毒双价（GI.1/GII.4）疫苗（汉逊酵母）全程免疫后14天的免疫原性。进一步评价在6月龄~59岁健康人群接种不同剂量试验疫苗的安全性；探索试验疫苗在6月龄~59岁健康人群中的免疫持久性。

[Translation]

To evaluate the immunogenicity of different doses of recombinant norovirus bivalent (GI.1/GII.4) vaccine (Hansen yeast) in healthy people aged 6 months to 59 years 14 days after full immunization. To further evaluate the safety of different doses of the experimental vaccine in healthy people aged 6 months to 59 years; to explore the immune persistence of the experimental vaccine in healthy people aged 6 months to 59 years.

Start Date29 Jun 2021

Sponsor / Collaborator

Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd

[+2]

100 Clinical Results associated with Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

Login to view more data

100 Translational Medicine associated with Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

Login to view more data

100 Patents (Medical) associated with Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

Login to view more data

4

Literatures (Medical) associated with Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

01 Feb 2013·VaccineQ3 · MEDICINE

Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge

Q3 · MEDICINE

Article

Author: Jimmy Kwang ; Fang He ; Mookkan Prabakaran ; Annasaheb B. Kolpe

The present study demonstrates the cross-protective efficacy of baculovirus displayed HAs of A/Indonesia/669/06 and A/Anhui/01/05 against heterologous H5N1 challenges in a mouse model. Mice orally or subcutaneously immunized with live bivalent-BacHA vaccine significantly induced higher HA-specific humoral and cellular immune responses when compared with inactivated bivalent-BacHA. In addition, oral administration of live bivalent-BacHA vaccine was able to induce significant level of antigen-specific mucosal IgA levels. Microneutralization assay indicated that live bivalent-BacHA vaccine was able to induce strong cross-clade neutralization titer against distinct H5N1 clades (1, 2.1.3, 2.2.1.1, 2.3.2, 2.3.4, 4, 7 and 9). The production of both interferon-gamma (IFN-γ) and interleukin-4 (IL-4) by splenocytes from vaccinated mice indicated that mice vaccinated orally or subcutaneously with live bivalent-BacHA stimulated both IFN-γ secreting Th1 cells and IL-4 secreting Th2 cells, whereas mice immunized subcutaneously with inactive adjuvanted bivalent-BacHA stimulated only IL-4 secreting Th2 cells. Cross-protective immunity study also showed that mice immunized either orally or subcutaneously with live bivalent-BacHA were completely protected against 5MLD50 of clade 1 and clade 2.2.1.1 H5N1 viral infections. The protective immune response elicited by bivalent-BacHA vaccine against H5N1 variants demonstrates the possibility of protection against a broad range of H5N1 strains.

01 Dec 2011·Antiviral ResearchQ2 · MEDICINE

Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine

Q2 · MEDICINE

Article

Author: Huanchun Chen ; Shaobo Xiao ; Liurong Fang ; Meilin Jin ; Zhen Li ; Qunfeng Wu ; Huiying Fan ; Wei Zou ; Yang Li ; Xiaoyue Su ; Jinfang Xu ; Wei Lu

The development of novel H5N1 influenza vaccines to elicit a broad immune response is a priority in veterinary and human public health. In this report, a baculovirus vector was used to construct bivalent recombinant baculovirus vaccine encoding H5N1 influenza virus hemagglutinin proteins (BV-HAs) from clade 2.3.4 and clade 9 influenza viruses. Mice immunized with 5×10(7) IFU BV-HAs developed significantly high levels of H5-specific neutralizing antibodies and cellular immunity that conferred 100% protection against infection with H5N1 influenza viruses. This study suggests that baculovirus-delivered multi-hemagglutinin proteins might serve as a candidate vaccine for the prevention of pre-pandemic and pandemic H5N1 influenza viruses.

01 Dec 2008·Veterinary MicrobiologyQ2 · AGRICULTURAL & FORESTRY SCIENCE

Pilot trials in Australia on eradication of footrot by flock specific vaccination

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: D.R. Lehmann ; R.J. Whittington ; O.P. Dhungyel

Footrot is a contagious disease of ruminants requiring strains of Dichelobacter nodosus that possess virulence factors including proteases and fimbriae. Sheep can be immunised against footrot using vaccine-containing fimbriae, either native or recombinant. The fimbriae are responsible for the serological K-agglutination reaction, which has been used to classify field isolates into nine major serogroups. The range of protection conferred by vaccination is largely restricted to the serogroup involved, but antigenic competition precludes effective vaccination with multivalent vaccines that contain all serogroups. However, vaccination with specific bivalent recombinant fimbrial vaccine led to eradication of virulent footrot from small ruminants in Nepal and the same result was obtained in Bhutan using a specific whole cell vaccine. In the study reported here two pilot trials have been conducted in Australian sheep flocks, one with a virulent form of footrot caused by a single serogroup F, and the other with an intermediate form also caused by a single serogroup C. In trial 1 pre-vaccination prevalence of clinical footrot in a group of randomly selected animals was 44%. This reduced to 2% at 3 months and 0.5% at 4 months, and there were no clinical cases at 5 months or at 16 months post-vaccination in the whole flock. Similarly in trial 2 pre-vaccination whole flock prevalence was 8.5%, while it was 2% at 3 months, 0.3% at 6 months and zero at 18 months post-vaccination. Use of flock specific monovalent whole cell vaccines over whole flocks for only one season and culling of the few non-responders has been a successful approach in eradication of the disease from both these flocks. This is the first study to report the successful use of specific vaccine for the intermediate form of footrot.

100 Deals associated with Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Norovirus Infections	Phase 3	CN	Sinopharm Zhongsheng Biotechnology Research Institute Co., Ltd	26 May 2023
Norovirus Infections	Phase 3	CN	Lanzhou Institute of Biological Products Co. Ltd.	26 May 2023
Norovirus Infections	Phase 3	CN	Beijing Bio-Institute Biological Products Co. Ltd.	26 May 2023